X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ENTR-601-44, a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the lead product candidate within Entrada’s Duchenne muscular dystrophy franchise.
Lead Product(s): ENTR-601-44
Therapeutic Area: Genetic Disease Product Name: ENTR-601-44
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
ENTR-601-44, a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the lead product candidate within its Duchenne franchise from Entrada’s growing pipeline of EEV-therapeutics.
Lead Product(s): ENTR-601-44
Therapeutic Area: Genetic Disease Product Name: ENTR-601-44
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
ENTR-601-44, a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the lead product candidate within its Duchenne franchise from Entrada’s growing pipeline of EEV-therapeutics.
Lead Product(s): ENTR-601-44
Therapeutic Area: Genetic Disease Product Name: ENTR-601-44
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
The agreement includes a four-year global research collaboration whereby Entrada will continue to advance for certain research activities related to ENTR-701 (EEV-conjugated phosphorodiamidate morpholino oligomer), as well as additional DM1-related research activities.
Lead Product(s): EEV-conjugated Phosphorodiamidate Morpholino Oligomer
Therapeutic Area: Genetic Disease Product Name: ENTR-701
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $735.0 million Upfront Cash: $224.0 million
Deal Type: Agreement February 09, 2023
Details:
ENTR-601-45 is a Endosomal Escape Vehicle-conjugated phosphorodiamidate morpholino oligomer, has the potential to restore the mRNA reading frame and allow for the translation of dystrophin protein, it Duchenne muscular dystrophy patients.
Lead Product(s): ENTR-601-45
Therapeutic Area: Genetic Disease Product Name: ENTR-601-45
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).
Lead Product(s): ENTR-601-44
Therapeutic Area: Genetic Disease Product Name: ENTR-601-44
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
ENTR-701, a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer, is the second novel clinical candidate from Entrada’s growing pipeline of EEV therapeutics.
Lead Product(s): EEV-conjugated Phosphorodiamidate Morpholino Oligomer
Therapeutic Area: Genetic Disease Product Name: ENTR-701
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $735.0 million Upfront Cash: $224.0 million
Deal Type: Collaboration December 08, 2022
Details:
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy.
Lead Product(s): ENTR-601-44
Therapeutic Area: Genetic Disease Product Name: ENTR-601-44
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
ENTR-601-44 (Exon 44 Skipping Oligonucleotide) is being developed for patients with DMD that are exon 44 skipping amenable. We plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ENTR-601-44 in 2022.
Lead Product(s): ENTR-601-44
Therapeutic Area: Genetic Disease Product Name: ENTR-601-44
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $181.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2021
Details:
The Company plans to use the investment proceeds to advance its diverse pipeline to the clinic. Included in this pipeline are several of Entrada’s oligonucleotide programs for the treatment of multiple neuromuscular diseases, led by Duchenne muscular dystrophy (DMD).
Lead Product(s): Oligonucleotide antibody
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Wellington Management Company
Deal Size: $116.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
